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The phylum Actinobacteria represents one of the most 
diverse groups of microorganisms in nature. These 
Gram- positive bacteria have a high GC content and 
show a remarkable range of morphologies, including 
unicellular cocci or rods (for example, members of the 
genera Micrococcus and Mycobacterium), and morpho-
logically complex multicellular bacteria (for example, 
members of the genera Amycolatopsis, Frankia and 
Streptomyces)1. Actinobacteria are widely distributed 
across both terrestrial and aquatic ecosystems, as well 
as in the microbiomes of higher eukaryotes2. This eco-
logical diversity is reflected in their metabolic potential 
as Actinobacteria are extremely versatile producers of 
bioactive natural products. Notably, Actinobacteria 
produce two thirds of all known antibiotics used in the 
clinic today, but also a vast array of anticancer com-
pounds, immunosuppressants, anthelmintics, herbicides 
and antiviral compounds, in addition to extracellu-
lar enzymes3–6. Therefore, these bacteria are attractive 
sources for clinical drugs4,7.
The introduction of antibiotics in the twentieth cen-
tury greatly contributed to the extension of the human 
lifespan and has saved millions of lives worldwide. 
However, with the increase in antibiotic resistance, 
we now face a huge challenge in treating infections 
by multidrug- resistant bacteria8. This coincides with 
a dramatic decrease in the success of traditional drug 
development through high- throughput screening9,10. 
Indeed, the chance of finding new antibiotics via tradi-
tional methods in randomly chosen Actinobacteria has 
been estimated at less than one per million11,12. However, 
advances in genome sequencing have unveiled a vast res-
ervoir of biosynthetic gene clusters (BGCs) for natural 
products in microbial genomes, even in those that had 
been studied extensively for decades13–15. The OSMAC 
strategy (one strain many compounds)16 for extensive 
mining of individual strains still yields promising new 
molecules17,18. However, the rate of success has decreased 
dramatically since the golden years of drug discovery, 
primarily due to replication12. The apparent failure to 
uncover the full potential of natural product- producing 
microorganisms is likely due to the fact that we lack the 
understanding that is required to activate the expres-
sion of their BGCs in the laboratory. During industrial 
screening, bacteria and fungi are typically grown in 
isolation with ample nutrients and resources, which is 
in sharp contrast to their natural complex and rapidly 
changing habitat. Antibiotics are believed to be impor-
tant for survival as mediators of resource competition 
in a competitive environment19,20, and microbial inter-
actions have a key role in their activation21–23. Hence, 
to increase the success of natural product- based drug 
discovery, we need to elucidate the triggers and cues that 
activate the expression of BGCs24,25.
Bioactive metabolites mediate important ecological 
functions, which are as diverse as their chemical struc-
tures. Siderophores enhance iron uptake in environments 
where the bioavailability of iron is limited26, pigments 
provide protection against ultraviolet radiation and 
have antioxidant activity27 and compatible solutes pro-
tect against osmotic stress28. However, the most obvious 
ecological purpose is biological weaponry to outcompete 
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other organisms for resource acquisition19,21. As produc-
ers of various bioactive molecules, Actinobacteria are 
attractive to eukaryotic hosts as symbionts. For instance, 
Streptomyces spp. that live in the antennal glands of bee-
wolf digger wasps produce antibiotics that protect the 
wasp larvae from various pathogenic fungi and bacte-
ria29, and endophytic Actinobacteria protect their host 
against phytopathogens2,30.
In this Review, we discuss why Actinobacteria excel 
as natural product producers and how their specialized 
metabolism and the regulatory mechanisms governing 
this metabolism have evolved in the context of ecology 
and genomic structure. Finally, we explore how ecologi-
cal insights can be translated into approaches for compu-
tational and experimental genome mining strategies that 
yield novel bioactive molecules, in particular antibiotics.
A mycelial lifestyle
The propensity to produce bioactive molecules and the 
richness of bacterial genomes in terms of BGC diversity 
have been correlated with key organismal features, such 
as multicellularity, endospore formation and genome 
size31,32. Bacteria can be divided broadly into two groups 
based on their adaptability: specialists and generalists, 
each with their own environmental niches. Specialists 
are dedicated to life in specific environments and there-
fore require less extensive metabolism and, accord-
ingly, smaller genomes33,34. Mycoplasma genitalium 
is a well- known example of an organism with a small 
genome of around 580 kb and fewer than 500 genes35. 
The smallest genomes known to date belong to parasites 
and symbionts, with the beetle symbiont Stammera spp. 
as a remarkable example of an organism with a small 
genome of around 270 kb and 250 genes36.
By contrast, generalists usually have larger genomes 
and a complex morphology, such as multicellularity and 
the formation of endospores33,34. Their ability to use 
multiple nutrient sources enables them to adapt to 
diverse environments and growth conditions, which 
requires complex metabolic regulation. Therefore, it is 
not surprising that this group of bacteria includes the 
most important producers of natural products such as 
Actinobacteria, Cyanobacteria and Myxobacteria34,37. 
Hallmark features of multicellularity and development 
include intraspecies communication, morphological 
differentiation and programmed cell death (PCD)38.
The linkage between morphological and chemical 
differentiation is best explained using Streptomyces as 
an example. Streptomycetes are mycelial organisms 
that reproduce by sporulation, with a life cycle similar 
to that of filamentous fungi. When the conditions are 
favourable, a single and uninucleoid spore will germi-
nate and the hyphae grow out by a combination of api-
cal growth and branching, which results in a complex 
mycelial network3,39. Exo- enzymes are released to break 
down natural polymers, such as cellulose, mannan and 
chitin, thereby providing nutrients. The vegetative hyphae 
are compartmentalized by occasional semi- permeable 
cross- walls to form large multinucleoid cells. The next 
step in the developmental programme is the formation 
of new sporogenic aerial hyphae, which eventually dif-
ferentiate into chains of uninucleoid spores3,39. To fuel 
the onset of the developmental programme, old vege-
tative mycelia are autolytically degraded through PCD 
to liberate the necessary nutrients for the new biomass40 
(Fig. 1). Eventually, reproductive aerial hyphae differenti-
ate into long chains of spores. The onset of development 
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Fig. 1 | From biological understanding to elicitation of BGCs. Upon environmental 
stress, such as nutrient starvation, programmed cell death (PCD) leads to the autolytic 
degradation of the old mycelia, which liberates the necessary nutrients to fuel the  
onset of development and the new biomass. The onset of morphological development 
correlates temporally with the production of antibiotics. Specifically, cell- wall 
peptidoglycan is recycled to release the amino sugars N- acetylmuramic acid (MurNAc) 
and N- acetylglucosamine (GlcNAc). GlcNAc is internalized as GlcNAc-6P and converted 
to GlcN-6P, which functions as a ligand for the global regulator DasR. Binding of GlcN-6P 
inactivates the repressor DasR, which results in the derepression of pathway- specific 
activators of antibiotic biosynthetic gene clusters (BGCs)49. The resulting production of 
antibiotics (such as calcium- dependent antibiotic (Cda), coelimycin P1 (Cpk) and 
actinorhodin (Act)) is likely to provide a line of defence to protect the nutrients that have 
been released by PCD against motile saprophytic bacteria, whereas the synthesis of 
DNA- degrading prodiginines (undecylprodigiosin (Red)) promotes PCD. GlcNAc elicits 
the transcription of BGCs that are not expressed under standard laboratory conditions 
and can thus be used in screening regimes for drug discovery.
Endospore
A dormant, non- reproductive 
structure that can survive for 
long periods of time and is 
important for dispersal of the 
organism in the environment.
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is controlled by the bld (bald) genes, so- called because 
mutants fail to produce the fluffy aerial mycelium41. 
Genes that control the distinct steps leading towards 
the maturation of aerial hyphae and subsequent sporu-
lation are called whi (white) genes, referring to the white 
appearance of mutants due to their failure to produce 
grey- pigmented spores42.
The onset of morphological development correlates 
temporally with the production of antibiotics43,44. The 
production of antibiotics is likely to provide a line of 
defence to protect the PCD- released nutrients against 
motile saprophytic bacteria, while at the same time, 
antibiotic- mediated lysis of these competitors may 
serve as an alternative food source3,38,45,46. Interestingly, 
prodiginines — which have DNA- damaging properties 
and are not secreted, and hence damage the DNA of the 
producer — apparently facilitate PCD in Streptomyces 
coelicolor47. This suggests that some antibiotics may even 
drive development via the initiation of PCD.
Missing signals and cryptic antibiotics
The genome sequences of extant Actinobacteria ‘doc-
ument’ their present and (recent) past ecology. They 
specify various functionalities — including the natural 
products they produce — used to cope with challenges 
that these bacteria face in their specific niches. Not sur-
prisingly, genome sequencing has had a huge impact 
on natural product discovery. This is exemplified by 
the specialized metabolism of S. coelicolor A3(2), the 
model organism for antibiotic biosynthesis. For a long 
time, this organism was known to produce four anti-
biotics, namely actinorhodin (Act), calcium- dependent 
antibiotic (Cda), undecylprodigiosin (Red) and the 
plasmid- encoded methylenomycin (Mmy). When 
the genome of S. coelicolor was sequenced, many more 
BGCs were uncovered than originally anticipated, and 
the same was true for other model streptomycetes13,14,48. 
Renewed efforts for drug discovery led to the surprising 
discovery of yet a fifth antibiotic in S. coelicolor, called 
coelimycin P1 (reF.49), in a model organism that had been 
studied by thousands of scientists in hundreds of labora-
tories around the world. Moreover, a novel branch of the 
biosynthetic pathway of the model polyketide actinor-
hodin was shown to be activated by co- cultivation with 
the fungus Aspergillus niger50, and mass spectral imag-
ing revealed substantial changes in the secreted metab-
olome during interaction of S. coelicolor with five other 
Actinobacteria23. These examples illustrate the concept 
of cryptic biosynthetic pathways, namely those that have 
been identified in the genome but the cognate natural 
products of which are not synthesized under laboratory 
conditions (Box 1). This concept has revolutionized the 
field of antibiotic research51, leading to the current era 
of genomics- based drug discovery3,4.
Nowadays, next- generation genome sequencing 
enables scientists to explore large numbers of micro-
organisms in search of novel BGCs. However, there are 
several challenges. A first challenge lies in prioritizing 
(cryptic) BGCs in terms of their potential for chemical 
novelty and/or clinical relevance to optimally exploit the 
wealth of available biological, genomic and metabolom-
ics data. Second, the bulk of the microorganisms in soil 
and marine environments resist cultivation under labo-
ratory conditions and thus represent a huge ‘white space’ 
of biochemical diversity52,53. Last, many BGCs are not 
expressed during laboratory cultivation. To unlock this 
potential, we need to better understand the ecological 
context in which Actinobacteria live, as this will provide 
clues to the mechanisms that activate the biosynthetic 
pathways of natural products. To leverage genome infor-
mation to this end, it is of major importance to under-
stand how such ecological forces shape actinobacterial 
genomes and how biosynthetic diversity evolves.
Evolution of biosynthetic repertoires
Vertical inheritance and horizontal gene transfer. The 
diversity of the environments that Actinobacteria inhabit 
is extraordinary2,54. Specialized metabolites have been 
isolated from marine organisms such as Salinispora spp.55, 
arctic Streptomyces nitrosporeus56, desert- dwelling 
Streptomyces spp.57 and species that live in the microbi-
omes of animals, insects and plants30,57–59. This ecolog-
ical diversity has major implications for the evolution 
of secondary metabolic repertoires, which are driven 
by a combination of vertical inheritance and horizontal 
gene transfer (HGT). In terms of vertical inheritance, 
Salinispora spp. show a strong relationship between phy-
logeny and BGC diversity, with close relatives sharing 
nearly all BGCs60. Similarly, in Amycolatopsis, BGCs 
are conserved within clades but not between them61. 
Programmed cell death
(PCD). A cellular suicide 
mechanism found in 
eukaryotes and prokaryotes 
that is activated in response to 
different stimuli, including 
biotic and abiotic stresses.
Vegetative hyphae
Long filamentous cells with 
multiple chromosomes that 
grow by tip extension and 
branching, forming a dense 
network into the surrounding 
substrate (often referred to as 
the vegetative or substrate 
mycelium).
Sporogenic aerial hyphae
reproductive hyphal structures 
that emerge from the 
vegetative mycelium into the 
air and develop into chains of 
unigenomic spores.
Saprophytic bacteria
Bacteria, often found in the 
soil, that feed on dead and 
decaying organic material.
Box 1 | Silent biosynthetic gene clusters
What we have learned from genome sequencing efforts it is that many of the biosynthetic 
gene clusters (bGcs) are not accounted for in the corresponding metabolomes.  
these bGcs are referred to as ‘silent’ or ‘cryptic’. Although these terms are sometimes 
interchanged, they have different meanings. A bGc is ‘cryptic’ when it has been identified 
but cannot yet be linked to a product, activity or phenotype. to establish whether a 
cluster is ‘silent’, experimental validation is required, at the level of gene expression or 
metabolomics (in case the compound is known). Silence of a bGc may reflect the fact 
that we do not yet understand the environmental conditions that are required for their 
expression. Alternatively, a bGc may have been silenced as a first step towards loss of 
the complete cluster. A transcriptome study of Salinispora strains revealed that more 
than half of their bGcs were expressed at levels that should facilitate discovery of the 
compounds they produce156. As transcriptome data of many bGcs are lacking, this 
suggests that most of the unexplored bGcs may be cryptic — that is, not linked to their 
products — rather than silent. For these bGcs, our failure to detect the corresponding 
metabolites is linked to other factors, such as translation efficiency and extraction 
methods.
Although the importance of ‘omics’- based natural product discovery is clear157, a 
proportion of bGcs remain transcriptionally silent in the laboratory. transcriptome 
analysis revealed that biosynthetic potential is more complicated than the presence  
or absence of a bGc alone, as a substantial proportion of the bGcs were differentially 
expressed between strains156. An argument often heard during discussions between 
scientists in the field is that if a few different isolates of the same species are analysed, 
only one of these may express the bGc in question. true transcriptional inactivity  
of bGcs may be due to a mutation in a structural or regulatory gene, although the 
former is less logical as the entire biosynthetic machinery would be produced in  
vain. An intriguing concept is that regulatory genes may sustain a single (frameshift) 
mutation, rendering the gene inactive, which may be easily restored by a compensatory 
mutation as a strategy for bet- hedging in a community, as seen for isolates of Streptomyces 
lunaelactis83. Such ‘light- switch silencing’ may be a primary mechanism by which strains 
are able to maintain large numbers of bGcs, as natural product biosynthesis is an energy- 
intensive process. Still, it is reasonable to assume for many of the silent bGcs that the 
right conditions for their transcriptional activation are lacking when the strain is grown 
in the laboratory.
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These BGCs may be more important for adaptation than 
for survival. Similarly, rapid demographic expansion of 
Streptomyces into previously uninhabited niches has 
led to differentiation into various species clusters, dis-
tinguishable from each other by ancestral homologous 
recombination events62.
HGT is another important evolutionary driver of chem-
ical complexity of natural products in Streptomyces60,63. 
In Salinispora, it has been estimated that up to 96% 
of the biosynthetic pathways may have been acquired 
through HGT60. It is unclear how frequent HGT occurs 
in Actinobacteria. Some argue that lateral acquisition 
and subsequent maintenance of complete BGCs is very 
rare64. Nevertheless, it is likely that HGT has a key role 
in shaping BGC repertoires. Many more ancient HGT 
events of complete BGCs will have occurred than those 
that can still be reliably inferred, because those BGCs will 
have diverged over time since the moment of transfer65. 
The large discordance between gene phylogenies of core 
biosynthetic genes and species phylogeny testifies to 
this66–68. When HGT leads to acquisition of BGCs with 
similar functions, there may be strong evolutionary pres-
sure for BGC loss. Indeed, in the evolutionary history of 
the genus Salinispora, genes for the biosynthesis of the 
siderophore desferrioxamine were lost in three strains 
independently as a direct consequence of HGT of a func-
tionally similar BGC. Such events may happen at a large 
scale and therefore could mask a large proportion of 
historical HGT events69. In fact, rates of HGT may vary 
strongly between different types of BGCs, depending 
on their ecological roles; many species have a conserved 
‘core’ set of BGCs, together with a strongly varying set of 
‘accessory’ BGCs that is acquired or exchanged through 
HGT61,70. This is evident in Amycolatopsis, in which 
BGCs that were acquired through HGT largely localize 
to non- conserved genomic regions61.
Chromosome structure. Genomic structure is intimately 
tied with genetic change and conservation in special-
ized metabolism, possibly both as cause and effect. 
Actinobacteria have either linear or circular chromo-
somes. In linear chromosomes, as seen in Streptomyces 
and Rhodococcus, strain- specific genes and BGCs that 
are incorporated through HGT tend to be localized in 
the unstable subtelomeric end regions of the chromo-
some63,71–73. Selective pressure might induce migration of 
such BGCs towards the chromosomal core, where they 
are likely more stably maintained through vertical inher-
itance and thus display much higher levels of conserva-
tion across different actinobacterial species71–73. A recent 
heterologous expression study also showed that the 
chromosomal location of BGCs has an effect on expres-
sion levels, with expression levels of a β- glucuronidase 
reporter gene measured highest in the central regions 
of the chromosomal arms74. In Streptomyces, more cen-
tralized BGCs tend to encode molecules such as ectoines 
and siderophores (Fig. 2), which are likely to be essential 
for survival of the genus. In the circular chromosomes 
of Salinispora and Amycolatopsis, species- specific BGCs 
are largely located on genomic islands relatively dis-
tant from the origin of replication75. Conversely, con-
served BGCs tend to be localized in the ‘core genome’. 
As in Streptomyces, in Amycolatopsis these BGCs spec-
ify metabolites, such as ectoines, siderophores and 
terpenes, whereas strain- specific BGCs, which make 
up as much as 67% of all BGCs in Amycolatopsis, 
localize largely away from the core genome to the 
genomic islands61. Although, to our knowledge, no 
studies have investigated BGC migration from periph-
eral regions to core regions, BGC migration between 
genomic islands has been inferred to be likely based 
on phylogenomic analyses, which supports the hypoth-
esis that BGCs preferentially migrate towards genomic 
core regions75.
One of the reasons why actinobacterial genomes are 
packed with BGCs is because there are well- established 
mechanisms in place to acquire and exchange BGCs. 
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Fig. 2 | BGC distribution and evolution in Streptomyces chromosomes. a | Distribution 
of biosynthetic gene clusters (BGCs) encoding terpenes, non- ribosomal peptides (NRPs), 
polyketides (PKs), siderophores and ectoines in 100 linear Streptomyces chromosomes. 
Clusters encoding type 1 PKs, type 3 PKs and NRPs localize to the chromosome ends, 
whereas clusters encoding type 2 PKs, terpenes, siderophores and ectoines localize more 
towards the chromosome core. b | Proposed movement of BGCs throughout evolution. 
Upon niche separation, genomes in different environments take up different genetic 
material through horizontal gene transfer (HGT) and/or BGCs are lost. In the long term, 
BGCs that are important for survival in that niche migrate towards the chromosome core 
and have a greater chance of being maintained through vertical inheritance.
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One common method of acquisition is through inte-
grative and conjugative elements (ICEs). These ICEs 
are plasmids with the ability to integrate themselves 
into the chromosome. The prevalence of these ICEs 
seems to be partially dictated by their ecological back-
ground: Actinobacteria originating from soil, plants 
or aquatic environments contain a greater number 
of ICEs than species from other environments76. In 
addition to ICEs, giant linear plasmids have a high 
density of BGCs for antibiotics, which suggests an 
important role in the acquisition of bioactive metabolites 
throughout evolution77–79.
Control of antibiotic production
Just as ecological forces shape the organization of BGCs 
across actinobacterial chromosomes, they also shape 
how the clusters are regulated. A range of external signals 
influence production either directly, through activation 
of pathway- specific activators, or indirectly, via an inter-
active network of pleiotropic regulators and intracellular 
signalling molecules44,80,81. Additionally, cross- regulation 
can exist between different BGCs, as was recently shown 
for the two chemically unrelated specialized metabolites 
antimycin and candicidin produced by Streptomyces 
albus S4. Their BGCs are separated by 9 kb on the chro-
mosome, but the pathway- specific regulator of candi-
cidin, FscR1, can bind directly upstream of the genes 
encoding antimycin biosynthesis and is essential for the 
activation of this cluster82. This regulatory complexity 
is highlighted by the strong emphasis on regulation in 
the genome of the model organism S. coelicolor, which 
encodes close to 800 regulatory proteins, representing 
>10% of the total proteome13. Higher- level control is 
likely to be tied to the ecological conditions in which 
these adaptive responses have evolved. Environmental 
and physiological signals have been integrated into the 
regulation of specialized metabolism to ensure that these 
costly molecules are only produced when required2,80. 
The involvement of environmental signals in the control 
and complexity of specialized metabolism is illustrated 
by the control of the BGC for ferroverdins and bagre-
mycins in Streptomyces lunaelactis83. The metabolite 
produced from the BGC depends on iron availability. In 
iron- limiting conditions, the antimicrobial bagremycins 
are produced. When there is an excess of iron, the amino 
group of bagremycin is replaced by a nitroso group to 
generate ferroverdin, a siderophore that is used as an 
anticholesterol drug and that, in nature, likely functions 
to limit iron- mediated oxidative damage83.
In a laboratory setting, the absence of the triggers 
and cues that would activate antibiotic production in 
the original habitat offers a possible explanation for 
why so many BGCs remain poorly expressed or silent 
under laboratory growth conditions (Box 1). However, 
the identity of environmental ligands and/or signals 
perceived by both pleiotropic and pathway- specific reg-
ulatory proteins is a major area of investigation and if 
resolved could lead to the activation of silent BGCs and 
thus drug discovery44. The key lies in understanding the 
biology of the producing bacteria and translating these 
insights into solutions to activate antibiotic production 
(see below).
Here, we provide some background on the complex 
transcriptional control of BGCs and then look into the 
regulatory networks that control the well- established 
connection between the onset of development and anti-
biotic production. For detailed reviews, we refer the 
reader elsewhere43,44,84.
Principles of the control of antibiotic production. To 
coordinate the metabolic responses to specific ecological 
challenges, Actinobacteria have evolved complex multi-
level regulatory networks. These networks are composed 
of multilevel transcriptional and translational control. 
This control is required for the correct interpretation of 
the signals that reach the colony and to translate them 
into appropriate responses. Much of our knowledge of the 
control of antibiotic production has been obtained from 
the study of the BGCs for Act, Cda and Red in S. coelicolor 
and for streptomycin in Streptomyces griseus43,44,84. These 
clusters are controlled by the pathway- specific acti-
vators ActII- ORF4, CdaR and RedD, which belong to 
the SARP family of Streptomyces antibiotic regulatory 
proteins85, and StrR (ParB- Spo0J family86), respectively. 
These cluster- situated regulators directly control the 
level of transcription of the BGC, which in turn dictates 
the production level of the cognate natural product87,88. 
Interestingly, actII- ORF4, cdaR and redD are all subject 
to translational control by the tRNA that recognizes the 
rare UUA codon for leucine. This tRNA, encoded by 
the bldA gene, is also required for the proper trans-
lation of many developmental genes and thus links 
morphological to chemical differentiation89,90.
Multiple cluster- situated regulators may control a sin-
gle BGC, and in addition the BGCs are subject to global 
control. This enables the cell to coordinate specialized 
metabolism with growth and development, the balance 
in carbon, nitrogen and phosphorus metabolism, and 
other major cellular pathways, thereby generating a com-
plex hierarchy of regulatory networks. To enable effi-
cient responses to external stimuli, the activity of many 
regulatory proteins is determined by small molecules. 
This includes the hormone- like γ- butyrolactones91,92, 
feedback through biosynthetic intermediates93–95 and 
sugar- based ligands96,97. The identification of such exter-
nal signals, often referred to as elicitors, is of key impor-
tance for the rational activation (elicitation) of natural 
product biosynthesis and thus for the revitalization of 
drug discovery.
PCD and the DasR regulatory network. As described 
above, PCD mediates the provision of nutrients at the 
onset of morphological and chemical differentiation. 
The signalling pathway from PCD to differentiation 
revolves around the global nutrient sensory GntR- 
family regulator DasR (Fig. 1). Autolytic degradation 
of cell- wall peptidoglycan releases the amino sugars 
N- acetylglucosamine (GlcNAc) and N- acetylmuramic 
acid (MurNAc) around the colonies. Under nutrient- 
limiting conditions (famine), the accumulation of 
GlcNAc around colonies triggers development and 
antibiotic production, whereas under rich growth 
(feast) conditions, GlcNAc blocks both processes97. 
The rationale behind this is that under feast conditions 
Ectoines
Bacterial specialized 
metabolites that act as 
osmolytes and protect against 
osmotic stress induced by, for 
example, changes in salt 
concentration of the 
environment.
Terpenes
A class of specialized 
metabolites produced by 
plants, fungi and bacteria with 
different biological activities, 
often volatile and with a strong 
odour.
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GlcNAc is seen as derived from chitin and signals 
nutrient abundance and promotes growth, whereas 
under famine conditions it signals hydrolysis of the 
bacterial cell wall and thus the need for development. 
GlcNAc- derived glucosamine-6- phosphate (GlcN-6P) 
and other phospho- sugars act as ligands for DasR, and 
thereby inactivate the repressor, which results in 
the derepression of BGCs97. DasR directly controls the 
pathway- specific activators of BGCs for all antibiot-
ics and siderophores in S. coelicolor98–100. Addition of 
GlcNAc under nutrient- limiting conditions activates 
the transcription of antibiotic BGCs, including cpk 
which specifies the cryptic polyketide coelimycin; this 
principle is now also being applied in industrial screen-
ing regimes. Interestingly, there is direct competition 
between the DasR regulon and the regulatory networks 
governed by the transcription factors AtrA and Rok7B7: 
DasR represses actII- ORF4 and nagE2, encoding the 
activator of Act biosynthesis and the GlcNAc trans-
porter, respectively, whereas these genes are activated 
by (and depend on) Rok7B7 and AtrA101. This system 
highlights the complex control of bioactive molecules 
in response to environmental changes. It also illustrates 
the value of discovering the ecological rationale behind 
antibiotic production and using such knowledge to 
activate antibiotic production (Fig. 1).
Identifying the elicitors that activate cryptic BGCs. 
Various other approaches have been developed to identify 
the environmental signals involved in the regulation of 
actinobacterial specialized metabolism. The signals that 
trigger the expression of BGCs act through a transcrip-
tional regulatory network, governed via cis- regulatory 
elements targeted by transcription factors. Many tran-
scription factors will respond to ligands, but how do we 
uncover what these ligands are? Genomic context is one 
major pointer. For example, if a regulatory gene lies next 
to a metabolic operon (such as for sugar metabolism), 
this may be an important clue. Additionally, transcription 
factors are often autoregulatory, and the cis- regulatory 
element is therefore typically found in the upstream 
region of the gene. With the cis- regulatory element in 
hand, computational approaches can then be used to pre-
dict the regulatory network in silico. In the case of DasR, 
it was immediately obvious that the best hits in those 
predictions all related to GlcNAc metabolism or trans-
port, and identifying glucosamine-6P as the ligand was 



















Fig. 3 | Natural products of Actinobacteria in host–microorganism and microorganism–microorganism interactions. 
Within the natural habitat of Actinobacteria, environmental signals are likely to have a key role in the activation of 
specialized metabolism. Chemical ecological interactions can, for example, be found in the rhizosphere of plants.  
Upon stress, plants release stress hormones (for example, jasmonic acid) via their root exudates. These hormones can 
activate antibiotic production by Actinobacteria, which can protect the plant against phytopathogens (‘cry for help’). 
Additionally, competitive interactions occur between different members of the microbial soil community (both symbionts 
and pathogens). Metabolites, such as siderophores and antibiotics, from the competing microbial community can elicit 
changes in the metabolic profile of Actinobacteria, including antibiotic production. These molecules have an important 
role in shaping the rhizosphere microbiome and inhibiting (opportunistic) pathogens, thus also protecting the host.
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bacterial producer strains include varying the compo-
sition of growth media102,103, inducing antibiotic resist-
ance104,105 and microbial co- cultivation106–108. Screening 
for new chemical elicitors of antibiotic production is a 
promising approach, as this can enhance the chance of 
success in high- throughput screening of bacterial strain 
collections. Logical elicitors to include in such screens are 
those with a proven pleiotropic activity, such as GlcNAc97, 
γ- butyrolactones92,109 and histone deacetylase inhibitors110. 
Screening compound libraries for small molecules 
that perturb antibiotic production was shown to be an 
effective strategy to identify novel elicitors of antibiotic 
produciton111. Another example is bioactivity high- 
throughput elicitor screening technology, in which a 
wild- type microorganism is subjected to a library of small 
molecules, and the resulting induced metabolomes 
are screened for bioactivity against a chosen indicator 
strain112,113. Use of this method led to the identifica-
tion of various cryptic antibiotics, including the novel 
lanthipeptide cebulantin112 and the novel naphthoqui-
none epoxide hiroshidine113. The method also identified 
atenolol, a β- blocker clinically used to treat hypertension, 
as a global elicitor113.
Chemical ecological relationships as elicitors of anti-
biotic production. Within their natural environment, 
Actinobacteria are part of diverse microbial commu-
nities that include archaea, bacteria, fungi, protists and 
viruses. Within these communities, specific interactions 
have evolved, and small molecules, such as specialized 
metabolites, facilitate interactions between different 
microbial species (symbionts or competitors), including 
the activation of antibiotic production114,115. By mimick-
ing these naturally occurring chemical–ecological rela-
tionships in so- called co- culture experiments, cryptic 
BGCs might be activated in the laboratory.
Indeed, co- cultivation of Actinobacteria with 
other bacteria or fungi changes their specialized 
metabolite production profile. Examples include the 
production of alchivemycin A by a Streptomyces strain 
following co- cultivation with the mycolic acid- producing 
Tsukamurella pulmonis116, biosynthesis of a range of 
metabolites during co- culture of Aspergillus nidulans 
and various streptomycetes117, and the activation of a 
silent pathway of actinorhodin in S. coelicolor upon 
co-cultivation with A. niger50. Co- culture of marine- derived 
Streptomyces spp. with different human pathogens, 
including methicillin- resistant Staphylococcus aureus, 
resulted in increased production of different antibi-
otics and enhanced biological activity118. Co- culture 
with multidrug- resistant bacteria might emerge as an 
effective, targeted approach to find novel bioactive com-
pounds with activity against the pathogens for which 
new antibiotics are desperately needed.
The signals and cues that mediate the observed 
changes in specialized metabolite production are diverse 
and include physical cell–cell interactions116,119, a higher 
rate of nutrient depletion120, enzymatic conversion of 
precursors to active metabolites121, HGT122 and microbial 
small molecules23,123,124. However, for many interactions, 
the signals — and specifically the molecular mechanisms 
— are as yet unknown. The development of analytical 
techniques such as nanospray desorption electro spray 
ionization and MALDI- TOF imaging mass spec-
trometry enables the direct visualization of molecules 
exchanged during the chemical communication between 
microorganisms125. These methods might help with the 
elucidation of the signals involved in above- described 
interactions.
Actinobacteria are also found in close association 
with various eukaryotic hosts (Fig. 3), and there are 
multiple examples of defensive symbioses between 
Actinobacteria and the host, in particular for plants (sup-
pressive soils) and insects (fungus- growing ants)54,126,127. 
An interesting example is provided by leafcutter ants, 
which live in symbiosis with the fungus Leucoagaricus 
and with Pseudonocardia bacteria127. The Pseudonocardia 
produce bioactive compounds to protect the fungal 
cultivar against infection by other fungi. Recent work 
showed that, in return, the presence of Pseudonocardia 
elicits the production of antimicrobials by pathogenic 
Escovopsis fungi during infection of the cultivar128. This 
exemplifies an evolutionary arms race between the 
Actinobacterium and the fungus.
Interestingly, many plant growth- promoting bac-
teria produce phytohormones, such as auxin and 
gibberelic acid129. This suggests that the host and the 
micro organism communicate (or hijack each other’s 
communication channels) through the production of 
such metabolites. This may indeed work both ways, as 
plant hormones influence growth and specialized meta-
bolism by endophytic Actinobacteria130 (A. van der Meij, 
J.M. Raaijmakers and G.P.v.W., unpublished observa-
tions), which reveals that host- specific signals can also 
affect specialized metabolism (Box 2).
Genome mining strategies
The biosynthetic diversity found in Actinobacteria 
is enormous. Genomic data sets have become 
increasingly larger, with massive strain collections, 
pan- genomes and metagenomes sometimes containing 
Box 2 | Host-derived signals as elicitors
the high abundance of Actinobacteria in plant microbiomes, specifically members of the 
genus Streptomyces, suggests that these bacteria are actively recruited by plants, possibly 
via root exudates158–160. Plants exudate up to 30–60% of their photosynthate into the 
rhizosphere, which contains large quantities of sugars and amino acids that can influence 
the growth of beneficial bacteria as well as their antibiotic production (for example, 
through catabolite repression)2,130,158. these exudates contain plant metabolites, such  
as the phytohormone salicylic acid, which has been positively correlated with the 
abundance of operational taxonomic units attributed to Streptomycetaceae in the soil,  
as well as endophytic Actinobacteria159. As such hormones are released under pathogenic 
stress, an interesting hypothesis is that exudation of such compounds may be a means  
to ‘cry for help’: the release of stress hormones by the host results in the recruitment  
of antimicrobial- producing Actinobacteria to reduce the severity of pathogenic 
infection2,161 (Fig. 3). Interestingly, when Actinobacteria are grown in the presence of 
plant stress hormones, such as jasmonic acid and salicylic acid, changes in the production 
of specialized metabolites are observed, often leading to increased antimicrobial activity130 
(A. van der Meij, J.M. Raaijmakers and G.P.v.W., unpublished observations). This could 
indicate that evolved regulatory networks exist between the host and members of its 
microbiome, opening up the intriguing possibility to design microorganisms that produce 
bioactive molecules specifically in response to stress induced by pathogen- derived 
signals. We hypothesize that similar use of Actinobacteria as ‘medicine producers’  
may happen in our own microbiome, with mammalian stress hormones as activators of 
specialized metabolism of Actinobacteria during infection.
Rhizosphere
The region of the soil and its 
microbial community 
immediately surrounding the 
plant root, which is directly 
influenced by root exudates.
www.nature.com/nrmicro
R e v i e w s
552 | OctOber 2020 | vOlume 18 
genetic information for thousands of Actinobacteria 
at once. A range of computational tools (for example, 
antiSMASH131 or PRISM132) have been developed in the 
past decade that automate the identification of BGCs 
in these genomes and, to a certain extent, facilitate 
prediction of the structures of their products (Box 3).
Given the increasing size of genomic or metagenomic 
data sets, studying BGCs on a case- by- case basis is often 
no longer feasible. To address this problem, sequence 
similarity networking approaches have been developed 
to automatically relate predicted BGCs to gene clusters 
of known function (from, for example, the MIBiG data-
base133) and to group them into gene cluster families 
(GCFs)32,60,134]. The members of a GCF are then pre-
dicted to produce the same or highly similar molecules. 
Using their streamlined computational framework for 
BGC similarity networking, researchers recently studied 
3,080 actinobacterial genomes and found that they con-
tained around ~18,000 distinct GCFs, the vast majority 
of which have no known products68. This constitutes an 
enormous potential for discovery and to some extent 
enables us to differentiate between BGCs that are likely 
to produce compounds we have seen before and BGCs 
that may encode novel chemistry. However, the number 
of GCFs to which no known functions or chemistries 
can be linked is so great that it is difficult to know which 
of the BGCs belonging to them encode the production of 
the pharmaceutically most interesting molecules.
Some advances have been made to predict the func-
tions of BGCs. For example, the Antibiotic Resistance 
Target Seeker (ARTS135) prioritizes BGCs based on 
co- localization with resistance genes. The rationale 
behind this is that bacteria need a mechanism to pro-
tect themselves against the antibiotic molecules they are 
producing. Therefore, resistance markers may function 
as beacons to prioritize specific BGCs for antibiotic dis-
covery. Unfortunately, only a small percentage of BGCs 
have distinguishable self- resistance markers. Ecological 
insights are needed to provide complementary strate-
gies to know which microorganisms are most likely to 
encode biosynthetic pathways of interest, which BGCs 
among these are functionally most desirable and how 
they can likely be activated.
Where to find chemical novelty. To effectively mine 
Actinobacteria for drug discovery, there is a need for 
guidance towards chemical novelty. First of all, this 
requires a better understanding of the environmental 
and taxonomic distributions of BGCs. Such knowledge 
can help estimate where to search for novel producers 
and whether this search should be based on phylog-
eny, geography or specific environmental niches31,61,134. 
Taxonomic groups that are particularly gifted in terms of 
their natural product diversity include Streptomycetales, 
Streptosporangiales, Frankiales, Micromonosporales 
and Pseudonocardiales134. To decrease the risk of redis-
covery of known molecules, known as replication, focus 
is directed towards rare Actinobacteria, of which many 
taxa have been greatly underexplored. Indeed, genera 
such as Micromonospora, Amycolatopsis, Salinispora, 
Nocardia and Verrucosispora are a source of chemically 
unique metabolites with potent antibacterial activities, 
such as abyssomycins and proximicins136. Besides phy-
logeny, geographic location has also been proposed as 
an indicator of BGC distribution137. However, compar-
ative genomics of Amycolatopsis and Salinispora strains 
both show that taxonomy is a more important indica-
tor of BGC distribution than geographic location55,60,61. 
Intriguingly, regardless of their geographic origin, strains 
of Salinispora arenicola all produced rifamycin, stauro-
sporine and saliniketal55, suggesting that, independent 
of the niche, strains may produce the same molecules or 
analogues. To a certain degree, “everything is everywhere 
and the environment selects”, as Dutch microbiologist 
Baas- Becking proposed almost a century ago. Indeed, a 
study of biosynthetic diversity in soils from Central Park 
in New York City, United States, suggests that the degree 
of novelty found in common areas may be similar to that 
in more exotic locations138.
Still, exploration of extreme or unusual environ-
ments, such as hyper- arid deserts, permafrost soils, 
mangrove trees, caves and deep- sea sediments that are 
characterized by challenging conditions (aridity, high 
salinity, low nutrient sources and extreme temperatures), 
showed high diversity of BGCs57,139. Between 2010 and 
2018 alone, taxonomically diverse microorganisms 
originating from extreme environments have been 
the source of nearly 200 new specialized meta bolites, 
many of which were produced by Actinobacteria57. 
Microorganisms from the permafrost soil synthesize 
a broad range of chemical compounds136. Other inter-
esting sources of gifted Actinobacteria are the micro-
biomes of diverse eukaryotic hosts, including insects, 
sponges and humans58,59,140. Within microbiomes, path-
ogen pressure selects for Actinobacteria that produce 
efficacious and relevant antimicrobials. Furthermore, 
this host association could potentially enrich for com-
pounds with low toxicity to animals. This makes host 
microbiomes a promising source of novel molecules, 
Box 3 | Computational tools for genome mining of biosynthetic diversity
the most commonly used tool for predicting biosynthetic gene clusters (bGcs) in 
bacterial genomes is antiSmASH. based on core genes, antiSmASH predicts the gene 
cluster type (non- ribosomal peptide, polyketide, terpene, siderophore and so forth).  
It also annotates and groups accessory genes and minimally predicts the specialized 
metabolite core scaffold, enabling researchers to quickly identify bGcs of interest in 
an uploaded genome131. For instance, antiSmASH output was used as the starting point 
for a phylogenetic prioritization method leading to the discovery of the novel compound 
corbomycin162. Other bGc identification tools also exist, such as bAGel and PrISm132,163. 
the database mIbiG, which charts known bGcs and their products, provides a means 
of easily comparing predicted clusters with experimentally characterized ones that 
have known chemical products133.
For bGc mining on a larger scale, the networking tool biG- ScAPe can be used to cluster 
both full and fragmented bGcs into gene cluster families, to obtain a comprehensive 
overview of bGc diversity in large genome collections or metagenomes. In such large 
data sets, the tool cOrASON can help with prioritizing bGcs of interest by providing 
insights into the evolutionary context of bGcs through phylogenetic analysis68. 
Genome mining approaches can also be combined with proteomics for more efficient 
prioritization164. Additionally, metabolomics data can be coupled to structure predictions 
yielded by genomics data or to absence–presence patterns of bGcs, in order to link 
molecules to bGcs165,166. the power of these methods will only increase now that tools  
are able to predict the function of natural products from their (predicted) structures167.  
As structure prediction is easier on a substructure level, there are ongoing efforts to 
attempt linking substructure predictions to mass shifts, which can be a great aid in 
elicitation studies and dereplication147.
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with possibly a higher potential to be successfully used 
in the clinic. Metabolomic analysis of Streptomyces 
spp. from insect microbiomes displayed immense 
potential for novel chemistry in these strains58. The 
same study demonstrated how principal component 
analysis can be leveraged for strain prioritization; a 
strain characterized as a metabolic outlier produced 
cyphomycin, a novel antifungal agent active against 
multidrug- resistant fungi58.
However, we should remind ourselves that even 
well- studied organisms such as S. coelicolor still harbour 
undiscovered biosynthetic pathways. For instance, it was 
shown that inactivation of the biosynthetic genes for the 
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resulted in the production of hidden antibiotics, such as 
the rare amicetin141. It is intriguing that despite the exten-
sive research into such organisms, metabolic products 
of several putative BGCs have so far eluded discovery. 
Also, there are still many exciting questions about the 
regulation of these specialized metabolite pathways, the 
signals that can activate production and the ecological 
role of many of these molecules. Even now, many les-
sons remain to be learned from S. coelicolor and other 
well- studied model streptomycetes. The challenge is to 
find ways to leverage this potential, and ecology can play 
a key role in this.
Ecology to identify BGCs of interest. Even when select-
ing Actinobacteria from under- mined taxa and from 
high- potential environments, one will still end up with 
thousands of distinct BGCs to study, many more than 
can realistically be targeted for experimentation with 
the currently available tools. Even the most high- tech 
synthetic biology approaches — although they are cer-
tainly game changers that allow bypassing regulation for 
specified BGCs — will not enable synthetic refactoring 
of sufficiently large numbers of BGCs to facilitate global 
screening of all actinobacterial biosynthetic diversity for 
years to come. One way to somewhat narrow down that 
number is to focus our attention on BGCs within non- 
core regions of actinobacterial genomes, which are more 
likely to encode compounds of chemical and functional 
novelty as HGT, and therefore the uptake of new, less 
conserved BGCs, mostly happens in these regions, as 
seen in Amycolatopsis61. However, even then there are 
still far too many BGCs to explore. Hence, further pri-
oritization is required. For this, genomic and meta- omic 
data are potentially very useful (Fig. 4).
First of all, predicting how BGCs are regulated can 
shed light on both their ecological functions and which 
triggers or cues can be used to activate their expression 
in the laboratory (Fig. 4b). Computational tools that 
predict regulons can help uncover the regulatory net-
works responsible for BGC control. One such tool is 
PREDetector142, which uses position weight matrices of 
transcription factor binding sites to predict which reg-
ulators are likely to bind DNA sequences within BGCs 
and thus likely regulate their expression. Often, a BGC 
encodes a pathway- specific regulator that is in turn 
regulated by a more pleiotropic (global) regulator. The 
identity of the global regulator can potentially be very 
informative about the ecological function of the BGC 
and therefore the function of its product. For example, 
in a plant microbiome setting, BGCs regulated by DasR 
are likely to respond to GlcNAc, which is also a break-
down product of fungal cell walls; hence, this could 
point to a possible antifungal role of a compound pro-
duced by such a BGC. Computational searches have the 
potency to identify the entire regulons associated with 
them142,143, and the gene content of these regulons may 
provide valuable data on the ecological functions of this 
regulon and by proxy of the BGC in question144. The spe-
cific molecules eliciting the activation of these regulons 
would then still need to be identified; potentially, paired 
metabolomics and metatranscriptomics of native com-
munities where the Actinobacterium resides may pro-
vide means to identify which molecules are specifically 
present when expression of the BGC is triggered. Such 
predicted regulatory cues can in turn feedback into tools 
such as PREDetector to find novel BGCs in other species 
that may be similarly elicited.
Furthermore, using metatranscriptomic data (or 
transcriptomic data of co- cultures) is likely to be a 
pow erful technology to predict the roles of BGCs in 
inter action with other organisms (Fig. 4c). Knowing 
under which conditions members of certain GCFs are 
expressed can illuminate their likely functions and hint 
towards how they may be regulated. For example, deter-
mining which bacterial BGCs in a plant endosphere 
microbiome were upregulated upon fungal infection 
recently led to the identification of a gene cluster essen-
tial for disease suppression145. The attractive concept 
that chitooligosaccharides produced from hydrolysis of 
the fungal cell wall elicit the production of the antifun-
gal needs to be tested. Additionally, expression of BGCs 
can be correlated to the absence/presence/abundance of 
specific other organisms in the community, to identify 
whether they might either be triggered by their pres-
ence or effectuate their loss from the community by, for 
example, antibiosis. Adding metabolomics to the equa-
tion may provide further means of prioritization, as 
candidate products for a BGC can be identified that spe-
cifically appear when it is expressed, and tandem mass 
spectrometry analysis algorithms146–150 can be used to 
dereplicate them and predict (parts of) their structures 
to assess their novelty (Box 3).
Synthetic biology approaches to express gene clusters. 
Although computational strategies can be used to pri-
oritize the most novel BGCs for experimental char-
acterization, we then face the challenge of identifying 
the cognate chemical products of these BGCs. This 
currently remains a bottleneck, as thousands of poten-
tially interesting BGCs can be found across publicly 
available genome sequences. By direct sequencing of 
environmental DNA, metagenomics even enables us 
to predict the chemical space of microbial ‘dark mat-
ter’: thus far uncultivated bacteria, which represent a 
promising source of novel natural products151. Synthetic 
biology is a powerful strategy to facilitate expression of 
BGCs observed in genome or metagenome sequences152. 
This strategy is illustrated by recent work on the 
Fig. 4 | Omics strategies for BGC prioritization and elicitation. a | Genomics- based 
prioritization of biosynthetic gene clusters (BGCs). After identifying putative BGCs 
through antiSMASH, BGCs can be prioritized based on commonalities and differences 
with known BGCs, their location on the genome, resistance markers in the vicinity of the 
BGC and predicted chemistry of the compound that the BGC produces. b | Genomics- 
based prediction of BGC regulatory sequences and elicitors. After predicting both known 
and unknown transcription factor binding sites (TFBS) with PREDetector, species with 
known TFBS can be directly elicited. Unknown TFBS can be characterized by generating 
a sequence profile of similar TFBS and searching the genome for the entire regulon 
regulated by the corresponding transcription factor. From this, the genes in the regulon 
can be functionally annotated, and the ecological signal that triggers BGC expression can 
be inferred. c | Transcriptomics- based prioritization of BGCs. Differential gene expression 
of BGCs can be quantified through RNA- sequencing (RNA- Seq) of co- cultures or 
microbiomes with or without a pathogen of interest. BGCs that are expressed when the 
pathogen of interest is present are more likely to have a role in targeting this pathogen 
and host protection.
◀
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identification of bioactive molecules from the human 
microbiome153. The synthesis of a metagenomic BGC 
and subsequent heterologous expression in S. albus ena-
bled the isolation and identification of new polyketides, 
designated metamycin A, metamycin B, metamycin C 
and metamycin D. Advances in synthetic biology and 
genome engineering (reviewed in detail in reF.152) can 
become very useful in the expression of cryptic BGCs 
and the identification of their chemical products. 
However, designing a DNA sequence for a large path-
way that will be functional in a model production host 
has remained more challenging than previously antici-
pated, as achieving the required stoichiometry between 
transcriptional units in a BGC for it to produce fully 
elaborated products is non- trivial154: the required pre-
cursors or cofactors may be lacking in the heterologous 
host155, and low production titres from synthetic BGCs 
may hamper chemical characterization. Although all of 
these bottlenecks are being addressed, understanding 
the regulatory mechanisms behind BGC expression for 
now remains of key importance for the identification of 
their products. Once high- throughput refactoring of 
complex BGCs becomes a reality, we anticipate that 
ecological and regulatory information will be crucial 
to predict BGC functions and thus prioritize them for 
synthesis and expression.
Conclusions and future perspectives
Despite our advances in niche exploration revealing 
great potential for drug discovery, the current state of 
knowledge regarding BGC diversity and distribution 
in terms of ecology and phylogeny limits our ability to 
guide drug discovery. It is therefore necessary to fur-
ther characterize the extant microbial diversity from 
different ecological niches and create a global survey of 
niche- correlated natural product diversity. Moreover, 
characterizing their functions in their native microbial 
communities, as well as their modes of action, will be 
crucial to advance our understanding of the regulation 
of specialized metabolism and hence for our effective 
ability to prioritize BGCs and elicit their expression. New 
technologies will be required for this, and in the ‘omics’ 
area we specifically envision a larger role for transcrip-
tomic and metatranscriptomic studies of specialized 
metabolism, as well as regulatory network reconstruc-
tion, targeted to the most relevant microbiomes and 
ecological niches. Once we better understand which cel-
lular and ecological conditions induce the expression of 
BGCs, this will greatly facilitate prioritizing gene clusters 
that are likely to have functions of interest and to predict 
which molecular stimuli are likely to activate them.
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